Ultragenyx Pharmaceutical Inc.
Rare disease therapeutics using gene therapy, enzyme replacement, and small molecule approaches
Updated · ultragenyx.com
- Sector
- Biotech
- Headquarters
- NOVATO, CA
- Founded
- 2010
- Latest Form D
- $75M, Dec 2012
- Total capital
- $109M
- Grants
- —
- No SBIR or STTR on record
- Sector median 1 award
- Raised
- $109M
- 4 Form D · Dec 2012
- 166 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 15 granted · 25 pending
- 20× sector median 2 patents
Capital Timeline
Federal ↑Equity ↓2010201120122013
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $75,000,005 | |
| Private capital raised | Form D · SEC | $15,100,000 | |
| Private capital raised | Form D · SEC | $18,664,443 | |
| Private capital raised | Form D · SEC | $133 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3383 | PepGen Inc. | — | $127M |
| 3384 | MouSensor, Inc. | — | — |
| 3385 | AGEX THERAPEUTICS INC | — | $19M |
| 3386 | Ultragenyx Pharmaceutical Inc. | — | $109M |
| 3387 | BlueSphere Bio, Inc. | — | $56M |
| 3388 | Life Biosciences LLC | — | $54M |
| 3389 | PhaseBio Pharmaceuticals Inc | — | $64M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Bill AliskiDirector
- William AliskiDirector
- WILLIAM ALISKIDirector
- Ben AuspitzDirector
- BEN AUSPITZDirector
- John DittonExecutive Officer
- JOHN DITTONExecutive Officer
- STEVEN JUNGLESExecutive Officer
Show all 20 people
- Emil KakkisDirector · Executive Officer
- EMIL KAKKISDirector · Executive Officer
- THOMAS KASSBERGExecutive Officer
- John KlockDirector
- CORDELIA LEONARDExecutive Officer
- Eran NadavDirector
- ERAN NADAVDirector
- SHALINI SHARPExecutive Officer
- Jenny SorianoDirector
- VIMAL SRIVASTAVAExecutive Officer
- Marten SteenDirector
- MARTEN STEENDirector
Patents
- Therapeutics For Glycogen Storage Disease Type IIIgranted
- Methods And Compositions For Treating Glycogen Storage Diseasesgranted
- Gene Therapy For Treating Propionic Acidemiagranted
- Gene Therapy For Treating CDKL5 Deficiency Disordergranted
- Novel Anion-exchange Chromatography Methods For Separation Of Empty From Full Recombinant Adeno-associated Virus Particlesapplication
- Methods For Improved Therapeutic Use Of Recombinant Aavapplication
- Sialylated Glycoprotein Composition And Uses Thereofapplication
- Compositions Of Triglycerides And Uses Thereofgranted
- Gene Therapy For Treating Propionic Acidemiaapplication
- Methods For Improved Therapeutic Use Of Recombinant Aavgranted
- Scalable Method For Producing Transfection Reagentsgranted
- Gene Therapy For Treating Propionic Acidemiagranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.